Trial reportThe Journal of experimental medicine1999
Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions.
Trial report in The Journal of experimental medicine, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 332 citations in OpenAlex.
- Trial
- Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.The lancet. Gastroenterology & hepatology · 2017Trial
- Trial
- T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity.PLoS medicine · 2005Trial
- Identifying Therapeutic Targets for Bronchial Asthma: Systematic Druggable Genome-Wide Mendelian Randomization.Health science reports · 2026Article
- Pathobiology and Regulation of Eosinophils, Mast Cells, and Basophils in Allergic Asthma.Immunological reviews · 2025Review
- Application of Nanoparticles for Immunotherapy of Allergic Rhinitis.International journal of nanomedicine · 2024Review
- Introduction of Heated Cow's Milk Protein in Challenge-Proven Cow's Milk Allergic Children: The iAGE Study.Nutrients · 2022Article
- From Allergen Molecules to Molecular Immunotherapy of Nut Allergy: A Hard Nut to Crack.Frontiers in immunology · 2021Review
- [Recombinant allergens, peptides, and virus-like particles for allergy immunotherapy].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2020Review
- Egg Allergy: Diagnosis and Immunotherapy.International journal of molecular sciences · 2020Review
- Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible?Frontiers in immunology · 2020Review
- Recombinant allergens for immunotherapy: state of the art.Current opinion in allergy and clinical immunology · 2019Review
- A novel role for neutrophils in IgE-mediated allergy: Evidence for antigen presentation in late-phase reactions.The Journal of allergy and clinical immunology · 2019Article
- Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches.Current allergy and asthma reports · 2018Review
- Impact of allergen immunotherapy in allergic asthma.Immunotherapy · 2018Review
- Genetic restriction of antigen-presentation dictates allergic sensitization and disease in humanized mice.EBioMedicine · 2018Article
- Dog and Cat Allergies: Current State of Diagnostic Approaches and Challenges.Allergy, asthma & immunology research · 2018Review
- Pathogenic CD4The Journal of allergy and clinical immunology · 2017Review
- Next generation immunotherapy for tree pollen allergies.Human vaccines & immunotherapeutics · 2017Review
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intradermal administration of short overlapping peptides derived from chain 1 of the cat allergen Fel d 1 (FC1P) that did not cross-link IgE, elicited isolated late asthmatic reactions with no visible early or late cutaneous response in 9/40 cat-allergic asthmatics. Four of the nine were human histocompatibility leukocyte antigen DR13-positive, as compared with only 1/31 nonreactors. The other five reactors expressed either DR1 or DR4. To confirm major histocompatibility complex restriction, fibroblast cell lines transfected with HLA-DR molecules were used to present FC1Ps to cat allergen-specific T cell lines derived from subjects before peptide injection. FC1P3 (peptide 28-44 of Fel d 1 chain 1) was recognized in the context of DR13 alleles (DRB1*1301, 1302) and induced specific T cell proliferation and IL-5 production. T cells from a DR1(+) responder proliferated and produced IL-5 in the presence of FC1P3 and DR1 (DRB1*0101) fibroblast cell lines, whereas T cells from a DR4(+) subject recognized FC1P2 (peptide 22-37) when presented by DRB1*0405. We conclude that short, allergen-derived peptides can directly initiate a major histocompatibility complex-restricted, T cell-dependent late asthmatic reaction, without the requirement for an early IgE/mast cell-dependent response, in sensitized asthmatic subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.